Special Update – NVAX – Novavax H7N9 Published In The NEJM – First Industry Vaccine For H7N9 Elicits Major Protective Immune Response In Blinding Speed – In a prestigious surprise, Novavax released its Phase I trial of 284 subjects injected with the H7N9 flu virus vaccine – published in the most recent online edition of[…]
November 7, 2013 Below is a pdf for MTSL Issue #767 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/11/MTSL-767-November-14-20131.pdf” save=”1″]
October 31, 2013 Below is a pdf for MTSL Issue #766 of the Medical Technology Stock Letter. [gview file=”http://www.bioinvest.com/wp-content/uploads/2013/11/MTSL-766-October-31-20131.pdf” save=”1″]
There is no excerpt because this is a protected post.
November 11, 2013 Sector Pullback Makes Biotech a Buy by Steven Halpern for The Daily Guru Despite the fact that the biotech sector has faced some setbacks recently, Jay Silverman, editor of Medical Technology Stock Letter, is confident it’s only the case of a normal correction. Steve Halpern: We’re here today with biotech sector expert,[…]
MTSL Special Update – Biotech Stocks – November 7, 2013 Biotech Stocks – Sell Off Accelerates As Investors Rush to Lock In 2013 Profits and “Risk Off” Includes Top Tier, Too. The current collapse was triggered by: a) Technical factors – A number of stocks failed to reach new highs despite bounces after the shock[…]
MTSL Issue #765 is now published from Bioinvest.
PCYC – ARIAâs Iclusig FDA Hold Indirectly Adds to PCYC Share Break In Biotech Bloodbath During Government Shutdown/GILD Stops Idelalisib CLL Study Early On Favorable Risk/Benefit. Biotech Meltdown Was Long Overdue, Painful In Short Run, Healthy For Long Run â Several MTSL Stocks Now Below BUY LIMITS. PCYC Is No ARIA Questions on whether the[…]
PCYC â Pharmacyclicsâ IMBRUVICA Gains FDA Approval For MCL; CLL Coming Soon â Reiterate BUY LIMIT and TARGET PRICE â In a watershed moment for oncology and biotech companies â PCYCâs ibrutinib, branded IMBRUVICA, has received FDA approval for patients with mantle cell lymphoma (MCL) who have been previously treated as a monotherapy. The drug[…]
PCYC â FDA Approves Rocheâs Gazyva (GA-101) In CLL, Bodes Well For Ibrutinib â JNJ/PCYC Going For Knockout Blow After Posting New Trials – BUY PCYC Before Approval The FDA has approved Roche/Genentechâs drug (GA-101) almost two months ahead of schedule (PDUFA 12/20/13, FDA Newsroom). As a reminder, Roche filed the BLA at the end[…]
CNDO – TSO Misses Primary and Second Endpoints in TRUST-I Crohn’s Study – Coronado announced disappointing TRUST-I results in Crohn’s disease. The trial missed both key endpoints – the primary endpoint was a change in CDAI score of >100 and the key secondary measure of remission, defined as achieving CDAI 150 points. In the corresponding[…]
The MTSL Issue #764 from Bioinvest is now published.
